Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 4/2020

30.06.2020

Safety and efficacy of short-term (1 to 3 months) dual antiplatelet therapy in patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials

verfasst von: Babikir Kheiri, Timothy F. Simpson, Mohammed Osman, Harsh Golwala, Qais Radaideh, Kris Kumar, Hind Rahmouni, Punag Divanji, Joaquin E. Cigarroa, Firas Zahr

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Among patients who have undergone percutaneous coronary intervention (PCI), the use of dual antiplatelet therapy (DAPT) is associated with increased risk of bleeding, but decreased stent thrombosis and myocardial infarction unrelated to the stent. As PCI techniques and devices have progressed, the optimal duration of DAPT has come into question. We identified all randomized controlled trials (RCTs) of patients undergoing PCI, who received one or more drug eluting stents (DES) for stable coronary artery disease (CAD) or acute coronary syndrome (ACS), and randomized to short (1–3 months) versus standard duration DAPT. The prespecified primary outcome was major adverse cardiovascular events (MACE). Important secondary outcomes were net adverse clinical events (NACE) defined as MACE and major bleeding; any bleeding; major bleeding; all-cause death; cardiovascular death. We calculated hazard ratios (HR) and 95% confidence intervals (CI) using random-effects model. Analysis included 7 RCTs, comprising 35,857 patients and 53,321 patient-years of follow-up. The mean (SD) age of patients was 64.4 (10.6) years, 49.6% of patients presented with ACS, and 25.5% were female. There was no difference between short and standard-length DAPT in regards to MACE (HR = 0.93; 95% CI 0.84–1.03; p = 0.19), NACE (HR = 0.93; 95% CI 0.85–1.02; p = 0.12), all-cause death (HR = 0.92; 95% CI 0.80–1.05; p = 0.21), or cardiovascular death (HR = 0.85; 95% CI 0.64–1.13; p = 0.26). However, short-term DAPT was associated with significantly reduced major bleeding events (HR = 0.67; 95% CI 0.47–0.95; p = 0.03) and any bleeding event (HR = 0.63; 95% CI 0.44–0.90; p = 0.01) compared with standard-length DAPT. Among patients undergoing PCI for CAD, the use of short-term DAPT (1–3 months) followed by single antiplatelet therapy was associated with a lower incidence of clinically relevant bleeding events, but with similar risk of MACE, all-cause death, and cardiovascular death compared with standard duration DAPT.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
3.
Zurück zum Zitat Valgimigli M, Bueno H, Byrne RA et al (2018) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 39:213–260CrossRef Valgimigli M, Bueno H, Byrne RA et al (2018) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 39:213–260CrossRef
4.
Zurück zum Zitat Levine GN, Bates ER, Bittl JA et al (2016) 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 68:1082–1115CrossRef Levine GN, Bates ER, Bittl JA et al (2016) 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 68:1082–1115CrossRef
6.
Zurück zum Zitat Moher D (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264CrossRef Moher D (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264CrossRef
10.
Zurück zum Zitat Hong M-K, Kim B-K, Shin D-H et al (2012) A new strategy for discontinuation of dual antiplatelet therapy: real safety and efficacy of 3 months dual antiplatelet therapy following endeavor zotarolimus-eluting stent implantation. J Am Coll Cardiol 60(15):1340–1348CrossRef Hong M-K, Kim B-K, Shin D-H et al (2012) A new strategy for discontinuation of dual antiplatelet therapy: real safety and efficacy of 3 months dual antiplatelet therapy following endeavor zotarolimus-eluting stent implantation. J Am Coll Cardiol 60(15):1340–1348CrossRef
12.
Zurück zum Zitat Vranckx P, Valgimigli M, Jüni P et al (2018) Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet 392(10151):940–949. https://doi.org/10.1016/S0140-6736(18)31858-0CrossRefPubMed Vranckx P, Valgimigli M, Jüni P et al (2018) Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet 392(10151):940–949. https://​doi.​org/​10.​1016/​S0140-6736(18)31858-0CrossRefPubMed
14.
Zurück zum Zitat Räber L, Magro M, Stefanini G et al (2012) Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation 125(9):1110–1121CrossRef Räber L, Magro M, Stefanini G et al (2012) Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation 125(9):1110–1121CrossRef
16.
Zurück zum Zitat Ozaki Y, Okumura M, Ismail TF et al (2010 Jun) The fate of incomplete stent apposition with drug-eluting stents: an optical coherence tomography-based natural history study. Eur Heart J 31(12):1470–1476CrossRef Ozaki Y, Okumura M, Ismail TF et al (2010 Jun) The fate of incomplete stent apposition with drug-eluting stents: an optical coherence tomography-based natural history study. Eur Heart J 31(12):1470–1476CrossRef
Metadaten
Titel
Safety and efficacy of short-term (1 to 3 months) dual antiplatelet therapy in patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials
verfasst von
Babikir Kheiri
Timothy F. Simpson
Mohammed Osman
Harsh Golwala
Qais Radaideh
Kris Kumar
Hind Rahmouni
Punag Divanji
Joaquin E. Cigarroa
Firas Zahr
Publikationsdatum
30.06.2020
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 4/2020
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-020-02069-9

Weitere Artikel der Ausgabe 4/2020

Journal of Thrombosis and Thrombolysis 4/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.